SCHEMBL536325

SCHEMBL536325

O=C(O)c1c(-c2ccccn2)noc1/C=C/c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 2/20 0.43
PKM P14618 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
GABRA5 P31644 2/20 0.42
F2 P00734 1/20 0.39
F12 P00748 1/20 0.39
KDM6B O15054 1/20 0.38
KDM4A O75164 1/20 0.38
KDM5C P41229 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
KDM3A Q9Y4C1 1/20 0.38
P2RX3 P56373 1/20 0.36
PIN1 Q13526 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536326 1.00 KDM4E (0.43) KDM4ELMNANPC1PKMRAB9A
SCHEMBL535861 0.83 GABRA5 (0.43) GABRA5P2RX3CYP1A2CYP2C19HSD17B10
SCHEMBL535860 0.83 GABRA5 (0.43) GABRA5P2RX3CYP1A2CYP2C19HSD17B10
SCHEMBL535778 0.82 KMT2A (0.50) LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL535779 0.82 KMT2A (0.50) LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL12543755 0.79 GABRA5 (0.54) KDM4ELMNAMAPTGABRA5KDM6B
SCHEMBL30684510 0.79 GABRA5 (0.54) KDM4ELMNAMAPTGABRA5KDM6B
SCHEMBL535835 0.79 GABRA5 (0.42) KDM4ELMNANPC1PKMRAB9A
SCHEMBL535834 0.79 GABRA5 (0.42) KDM4ELMNANPC1PKMRAB9A
SCHEMBL409574 0.77 PTPN1 (0.46) KDM4ELMNANPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414354-B1 Hydroxy-methyl isoxazole derivatives as gaba a modulators HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-8222246-B2 Substituted isoxazoles HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
EP-2414354-A1 Hydroxy-methyl isoxazole derivatives as gaba a modulators F. Hoffmann-La Roche AG (CH) 2012-02-08 EP disclosed
WO-2010112475-A1 HYDROXY-METHYL ISOXAZOLE DERIVATIVES AS GABA A MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 WO disclosed
US-20100256127-A1 SUBSTITUTED ISOXAZOLES ROCHE PALO ALTO LLC 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256127-A1 SUBSTITUTED ISOXAZOLES GABRA5, GABRA1, GABRA3 KDM4E 1060/4885LMNA 4042/4885NPC1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.